Salvage Therapy with Bevacizumab–Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series

摘要: We present a case series of seven patients with metastatic renal cell carcinoma treated bevacizumab (10 mg/kg) in combination sunitinib 25-50 mg as salvage therapy after disease progression under monotherapy. Two had partial response, four stable disease, and one patient progression. After median follow-up 17.2 mo, progression-free survival overall were 8.5 15.1 respectively. experienced exacerbation their preexisting hypertension; there no grade 4 toxicities. The bevacizumab-sunitinib sunitinib-refractory seems active has tolerable toxicity profile.